Mofegiline
Mofegiline (MDL 72,974A) is a drug that acts as a selective inhibitor of the enzyme monoamine oxidase B (MAO-B). This enzyme is involved in the breakdown of neurotransmitters such as dopamine, making mofegiline of interest in the treatment of neurological conditions such as Parkinson's disease. By inhibiting MAO-B, mofegiline increases the availability of dopamine in the brain, which can help to alleviate the symptoms of Parkinson's disease, a condition characterized by reduced dopamine levels.
Pharmacology[edit | edit source]
Mofegiline's mechanism of action involves the selective inhibition of monoamine oxidase B, an enzyme that degrades dopamine, a critical neurotransmitter in the regulation of movement, mood, and reward. Unlike non-selective monoamine oxidase inhibitors (MAOIs) that affect both MAO-A and MAO-B enzymes and can lead to significant side effects and dietary restrictions, mofegiline's selectivity for MAO-B allows for increased dopamine levels without the same level of risk.
Clinical Use[edit | edit source]
While mofegiline showed promise in early clinical trials for the treatment of Parkinson's disease, its development was eventually discontinued. The reasons for this are not detailed in public records but could include a range of factors from lack of efficacy in larger trials, safety concerns, or commercial decisions. Despite this, the study of mofegiline has contributed to the understanding of MAO-B's role in neurodegenerative diseases and the potential for selective inhibitors in therapeutic applications.
Research[edit | edit source]
Research on mofegiline has provided valuable insights into the pharmacological targeting of MAO-B as a strategy for increasing dopamine levels in the brain. This has implications not only for Parkinson's disease but also for other conditions characterized by reduced dopamine activity, such as certain forms of depression and neurodegenerative disorders. The development and study of mofegiline have helped pave the way for other MAO-B inhibitors that are currently in use or under investigation.
See Also[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
